For patients with moderate to severe plaque psoriasis
Embrace the chance of completely clear skin
- With Taltz, up to 90% of people saw a significant improvement of their psoriasis plaques
- 4 out of 10 achieved completely clear skin
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
- Psoriatic arthritis is the second approved indication for Taltz in the United States1 -
INDIANAPOLIS, December 1, 2017 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).1 Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1
"PsA is a chronic, progressive and painful form of inflammatory arthritis that impacts approximately 1.6 million Americans living with the disease," said Christi Shaw, president, Lilly Bio-Medicines. "We are proud to offer a new treatment option that can provide improvements in joint symptoms for these patients, further demonstrating Lilly’s overall commitment to immunology."
Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.1 Taltz should not be used in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.1 Taltz may increase the risk of infection.1 Other warnings and precautions for Taltz include pre-treatment evaluation for tuberculosis, hypersensitivity reactions, inflammatory bowel disease and immunizations.1 See Important Safety Information below.1
The efficacy and safety of Taltz was determined from findings from two randomized, double-blind, placebo-controlled Phase 3 studies – SPIRIT-P1 and SPIRIT-P2 – which included more than 670 adult patients with active PsA.1 SPIRIT-P1 evaluated the safety and efficacy of Taltz compared to placebo in patients with active PsA who had never been treated with a biologic disease-modifying antirheumatic drug.1 SPIRIT-P2 evaluated the safety and efficacy of Taltz compared to placebo in tumor necrosis factor inhibitor (TNFi)-experienced patients with active PsA who failed one or two TNF inhibitors.1 Across both studies, patients were required to have a diagnosis of active PsA for at least six months and at least three tender and three swollen joints.1 Non-responder imputation (NRI) methods were used. Inadequate responders (defined by blinded tender and swollen joint count criteria) at Week 16 received rescue therapy and were analyzed as non-responders.1
In studies of biologic-naïve and TNFi-experienced patients, the primary efficacy endpoint was the proportion of patients at 24 weeks achieving ACR20 response, which represents a 20 percent reduction in a composite measure of disease activity as defined by the American College of Rheumatology (ACR).1 Results from both studies demonstrated that patients treated with Taltz achieved significant improvement in joint symptoms, as measured by ACR20, compared with placebo.1 At 24 weeks, patients achieved ACR20 at the following response rates:
"For patients with PsA, treatment goals often include improvement in joint symptoms," said Philip Mease, M.D., Swedish Medical Center and University of Washington. "Based on the study results, Taltz can provide significant improvement in joint symptoms for patients who had never been treated with a biologic disease-modifying antirheumatic drug as well as patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors."
Lilly will work with insurers, health systems and providers to ensure patients are able to access this treatment. Patients, physicians, pharmacists or other healthcare professionals with questions about Taltz should contact The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979) or visit www.lilly.com.
Taltz is approved for the treatment of adults with active psoriatic arthritis.1 Taltz is also approved to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis.
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.
IX HCP ISI 01DEC2017
Psoriatic arthritis (PsA) is a chronic, progressive form of inflammatory arthritis that can cause swelling, stiffness and pain in and around the joints and impaired physical function.2 It occurs when an overactive immune system sends out faulty signals that cause inflammation, leading to swollen and painful joints and tendons.2 Psoriatic arthritis can affect peripheral joints in the arms and legs (elbows, wrists, hands and feet).2 If left untreated, PsA can cause permanent joint damage.2 Up to 30 percent of people with psoriasis also develop PsA.2
Taltz® (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.1 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.1 Taltz inhibits the release of pro-inflammatory cytokines and chemokines.1
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high- quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for moderate-to-severe plaque psoriasis and active psoriatic arthritis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
1 Taltz Prescribing Information, 2017.
2 Ritchlin C, et. al. Psoriatic Arthritis. New England Journal of Medicine. 2017;376:957-70.
PP-IX-US-1745 12/2017 ©Lilly USA, LLC 2017. All rights reserved.
Embrace the chance of completely clear skin
Embrace the chance
Taltz is a prescription medicine used to treat adults with active psoriatic arthritis. Taltz is also a treatment for adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
Do not use Taltz if you have had a severe allergic reaction to ixekizumab or any of the other ingredients in Taltz. See the Medication Guide for a complete list of ingredients in Taltz. If you have a severe allergic reaction, do not take another injection of Taltz.
Taltz is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. Taltz may increase your risk of infections, which can sometimes become serious.
Before starting Taltz, tell your HCP(s) if you
After starting Taltz, call your HCP right away if you have any of the symptoms of infection listed above. Do not use Taltz if you have any symptoms of infection, unless you are instructed to by your HCP.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taltz may cause serious side effects, including
The most common side effects of Taltz include: injection site reactions, nausea, fungal infections, and upper respiratory infections. These are not all of the possible side effects of Taltz. Tell your HCP about any side effect that bothers you or that does not go away.
Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch or call 1-800-FDA-1088.
Store Taltz in the refrigerator, and protect it from light. Do not freeze Taltz or use Taltz if it has been frozen. Do not shake Taltz.
Taltz is available by prescription only.
IX CON ISI 31AUG2016
Questions about Taltz? Call:
If you are a US healthcare provider, click "I agree" to continue. If you are not a US healthcare provider, please click "Cancel" below.
Click “Continue” to leave site or “Return to taltz.com” to close this window and return to taltz.com.
By using the Taltz Savings Card ("Card"), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below:
Offer void where prohibited by law. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program. If you live in Massachusetts, the Card expires on the earlier of: (i) the expiration date of this Card (December 31, 2018); (ii) the date an AB-rated generic equivalent for Taltz becomes available; or (iii) July 1, 2017, absent a change in Massachusetts state law. Available only in the US and Puerto Rico for residents of the US and Puerto Rico.
By accepting this offer, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you should notify your insurance carrier of your redemption of this Card. This offer is not valid with any other program, discount, incentive, or similar offer involving Taltz. It is prohibited for any person to sell, purchase or trade; or to offer to sell, purchase or trade; or to counterfeit this Card. This offer may be terminated, rescinded, revoked, or amended by Lilly USA, LLC, at any time without notice. This Card is not health insurance. This Card expires on 12/31/2018. Patients must first use their card by 12/31/2016 and are eligible for savings for up to 24 months of therapy.
*Pay no more than $25 monthly and as little as $5 monthly. $5 Monthly offer subject to a maximum annual benefit of $16,000. $25 Monthly offer subject to a monthly and annual cap of usual and customary pharmacy charges. If you meet program eligibility requirements, have commercial insurance, and your insurance provider covers Taltz, you are eligible to pay $5 monthly. If you meet program eligibility requirements, have commercial insurance, and your insurance provider denies coverage for Taltz after 2 requests for coverage attempts, you are eligible to pay $25 monthly. To participate in the $25 monthly program, eligible patients will need to contact Taltz Together to verify eligibility. To continue to participate in the $25 program, patients who qualify for the $25 monthly program are required to have a new benefits investigation and request for coverage completed 3 months post program initiation, 6 months post program initiation, and then every 6 months thereafter, as well as in January of every year, to verify coverage status and potential eligibility for the $5 monthly program. Card activation for both the $5 and $25 monthly programs is good for up to 24 months from patient qualification into the program. Subject to the terms and conditions of the program, patients may be eligible to re-enroll provided they continue to meet program criteria.
† Eligibility Criteria: By using the Taltz Savings Card ("Card"), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below:
Offer void where prohibited by law. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program. If you live in Massachusetts, the Card expires on the earlier of: (i) the expiration date of this card (December 31, 2020); (ii) the date an AB-rated generic equivalent for Taltz becomes available; or (iii) June 30, 2019, absent a change in Massachusetts state law. Available only in the US and Puerto Rico for residents of the US and Puerto Rico.
By accepting this offer, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you should notify your insurance carrier of your redemption of this Card.This offer is not valid with any other program, discount, incentive, or similar offer involving Taltz. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase or trade; or to counterfeit this Card. This offer may be terminated, rescinded, revoked or amended by Lilly USA, LLC, at any time without notice. This Card is not health insurance. This Card expires on 12/31/2020. Patients must first use their card by 12/31/2018 and are eligible for savings for up to 24 months of therapy.